Get the Stockscreener App
6.75
0.15%
0.05
Aligos Therapeutics Inc stock is traded at $6.75, with a volume of 7,176.
It is up +0.15% in the last 24 hours and down -16.13% over the past month.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
See More
Previous Close:
$6.80
Open:
$6.85
24h Volume:
7,176
Relative Volume:
0.10
Market Cap:
$40.86M
Revenue:
$7.97M
Net Income/Loss:
$-75.74M
P/E Ratio:
-0.2779
EPS:
-24.2853
Net Cash Flow:
$-85.33M
1W Performance:
-1.45%
1M Performance:
-16.13%
6M Performance:
-33.24%
1Y Performance:
-63.45%
1-Day Range:
$6.64
$7.1899
1-Week Range:
$6.23
$7.1899
52-Week Range:
$3.76
$18.99
Aligos Therapeutics Inc Stock (ALGS) Company Profile
Name
Aligos Therapeutics Inc
Sector
Industry
Phone
(800) 466-6059
Address
ONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO
Compare ALGS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALGS
Aligos Therapeutics Inc
|
6.64 | 41.84M | 7.97M | -75.74M | -85.33M | -24.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
485.72 | 121.15B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.07 | 82.43B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
830.33 | 52.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.60 | 44.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
366.48 | 40.07B | 4.98B | 69.60M | 525.67M | 0.5198 |
Aligos Therapeutics Inc Stock (ALGS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-18-25 | Resumed | H.C. Wainwright | Buy |
| Aug-19-24 | Initiated | H.C. Wainwright | Buy |
| Jan-06-23 | Upgrade | Jefferies | Hold → Buy |
| Jan-06-23 | Upgrade | Piper Sandler | Neutral → Overweight |
| Mar-23-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jan-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-09-21 | Initiated | SVB Leerink | Outperform |
| May-17-21 | Resumed | Piper Sandler | Overweight |
| Nov-10-20 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-10-20 | Initiated | JP Morgan | Overweight |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Piper Sandler | Overweight |
View All
Aligos Therapeutics Inc Stock (ALGS) Latest News
Aligos Therapeutics (ALGS) Reports Encouraging Findings at CROI 2026 - GuruFocus
Aligos Therapeutics Presents Positive Data at the Conference on Retroviruses and Opportunistic Infections (CROI) - The Manila Times
Aligos data hint at high hepatitis B viral suppression, new COVID protease drug - Stock Titan
Aug PostEarnings: Will Aligos Therapeutics Inc outperform its industry peersWeekly Profit Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Will Aligos Therapeutics Inc outperform its industry peersWeekly Profit Recap & High Accuracy Buy Signal Tips - baoquankhu1.vn
Trading the Move, Not the Narrative: (ALGS) Edition - Stock Traders Daily
Will Aligos Therapeutics Inc. benefit from current market trends2025 Stock Rankings & AI Forecast Swing Trade Picks - mfd.ru
What are the future prospects of DWSNMarket Movement Recap & Expert Verified Stock Movement Alerts - baoquankhu1.vn
Can Aligos Therapeutics Inc. weather a recessionMarket Weekly Review & Daily Profit Maximizing Trade Tips - mfd.ru
Rally Mode: What analysts say about Aligos Therapeutics Inc stockMarket Performance Summary & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Aligos Therapeutics: Pipeline Progress and Financial Runway Under the Microscope - AD HOC NEWS
(ALGS) Volatility Zones as Tactical Triggers - Stock Traders Daily
Aligos Therapeutics Appoints New Principal Accounting Officer - The Globe and Mail
Aligos Therapeutics (ALGS) appoints Nikhil Aneja as new Principal Accounting Officer - Stock Titan
Aligos Therapeutics Grants Non-Qualified Stock Options to New Employees as Part of Inducement Plan - Quiver Quantitative
Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Biotech Aligos gives new hires options on 81,100 shares - Stock Titan
Aligos Therapeutics secures $105 million in private placement - MSN
Price-Driven Insight from (ALGS) for Rule-Based Strategy - Stock Traders Daily
Aligos Therapeutics edges higher after update on Phase 2 HBV trial - MSN
Aligos Therapeutics stock maintains Buy rating at H.C. Wainwright on pevifoscorvir progress - Investing.com
Aligos reports progress on Phase 2 hepatitis B drug study By Investing.com - Investing.com Australia
Aligos Therapeutics stock rises on Phase 2 HBV study progress By Investing.com - Investing.com Nigeria
Aligos Therapeutics stock rises on Phase 2 HBV study progress - Investing.com
Aligos Therapeutics Provides Phase 2 B-SUPREME Study Progress Updates - Investing News Network
ALGS Executive Vice President and Chief Medical Officer Resigns - GuruFocus
Aligos Therapeutics (ALGS) Updates on Phase 2 Study for Hepatitis B Treatment - GuruFocus
Aligos reports progress on Phase 2 hepatitis B drug study - Investing.com
Aligos Therapeutics provides phase 2 B-SUPREME study progress updates - marketscreener.com
Aligos Therapeutics, Inc. Provides Phase 2 B-Superme Study Progress Updates - marketscreener.com
ALGS: Piper Sandler to Host Virtual Meeting on January 22 - GuruFocus
Lobbying Update: $80,000 of ALIGOS THERAPEUTICS INC. lobbying was just disclosed - Quiver Quantitative
(ALGS) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Aligos’ New Phase 1 Hepatitis B Study Signals Steady Progress in High-Need Market - TipRanks
Aligos therapeutics appoints James Hassard as chief commercial officer By Investing.com - Investing.com Nigeria
Geopolitics Watch: Why retail investors favor Aligos Therapeutics Inc stockPrice Action & Risk Controlled Daily Plans - Bộ Nội Vụ
Why retail investors favor Aligos Therapeutics Inc. stockInflation Watch & Verified Swing Trading Watchlist - Bộ Nội Vụ
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of James Hassard as Executive Vice President, Chief Commercial Officer - Investing News Network
Aligos Therapeutics looks to raise $105 million in private placement - MSN
Aligos therapeutics appoints James Hassard as chief commercial officer - Investing.com India
Aligos Therapeutics strengthens senior leadership team with the appointment of James Hassard as executive vice president, chief commercial officer - marketscreener.com
Aligos Therapeutics Presents Positive Data at HEP-DART 2025 - Investing News Network
Why Aligos Therapeutics Inc. stock could be next big winnerJuly 2025 Recap & Accurate Entry and Exit Point Alerts - ulpravda.ru
Aligos Therapeutics (NASDAQ:ALGS) Earns Buy Rating from Analysts at UBS Group - Defense World
UBS Group Upgrades Aligos Therapeutics (NASDAQ:ALGS) to "Strong-Buy" - MarketBeat
Why analysts upgrade Aligos Therapeutics Inc. stock2025 Market Trends & Community Consensus Trade Signals - Улправда
How resilient is Aligos Therapeutics Inc. stock in market downturnsJuly 2025 Rallies & Free Fast Entry Momentum Trade Alerts - Улправда
Why analysts remain bullish on Aligos Therapeutics Inc. stockJuly 2025 Movers & Daily Volume Surge Trade Alerts - Улправда
Trend Recap: Does Aligos Therapeutics Inc. stock trade at a discount to peers2025 Price Action Summary & Daily Stock Trend Watchlist - ulpravda.ru
Aligos Therapeutics Inc Stock (ALGS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.09%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):